Nutex Health Inc. — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
For Q2 2026 (three months ended June 30), Nutex reported net income of $65.8M and diluted EPS of $9.38, a dramatic swing from a $17.7M loss and $(2.95) EPS in Q2 2025. However, total revenue fell 13.6% to $210.8M (from $244.0M) due to normalizing IDR-related gains from 2025. A retroactive HaloMD amendment (effective May 1, 2024, finalized June 30, 2026) and CMS fee reduction cut contract services expenses by $52.3M in the quarter, driving approximately 25-30% ongoing expense reduction prospectively.
Why this rating
Major profitability reversal and structural cost reduction are material to a $524M company; revenue decline and dependency on regulatory arbitration changes create uncertainty offset by strong cash generation ($109.7M H1 2026 operating cash flow).
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.